314 related articles for article (PubMed ID: 19169287)
1. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
Escalón MP; Stefanovic A; Venkatraman A; Pereira D; Santos ES; Goodman M; Byrnes JJ; Fernandez HF
Bone Marrow Transplant; 2009 Jul; 44(2):89-96. PubMed ID: 19169287
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Kim JG; Sohn SK; Chae YS; Yang DH; Lee JJ; Kim HJ; Shin HJ; Jung JS; Kim WS; Kim DH; Suh C; Kim SJ; Eom HS; Bae SH
Bone Marrow Transplant; 2007 Nov; 40(10):919-24. PubMed ID: 17846602
[TBL] [Abstract][Full Text] [Related]
3. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
4. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma.
Yusuf RZ; Dey B; Yeap BY; McAfee S; Attar E; Sepe PS; Dube C; Spitzer TR; Ballen KK
Bone Marrow Transplant; 2009 Jan; 43(1):37-42. PubMed ID: 18794868
[TBL] [Abstract][Full Text] [Related]
5. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
6. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma.
de Magalhaes-Silverman M; Lister J; Rybka W; Wilson J; Ball E
Bone Marrow Transplant; 1997 Apr; 19(8):777-81. PubMed ID: 9134168
[TBL] [Abstract][Full Text] [Related]
7. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
8. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.
Yoon DH; Lee DH; Choi DR; Sohn BS; Kim S; Kim SW; Lee JS; Lee SW; Huh J; Suh C
Bone Marrow Transplant; 2011 Jan; 46(1):105-9. PubMed ID: 20383213
[TBL] [Abstract][Full Text] [Related]
12. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
14. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C
Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
[TBL] [Abstract][Full Text] [Related]
15. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
16. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
17. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
19. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
Kröger N; Hoffknecht M; Hänel M; Krüger W; Zeller W; Stockschläder M; de Wit M; Weh HJ; Kabisch H; Erttmann R; Zander AR
Bone Marrow Transplant; 1998 Jun; 21(12):1171-5. PubMed ID: 9674847
[TBL] [Abstract][Full Text] [Related]
20. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.
Talamo G; Claxton DF; Dougherty DW; Ehmann CW; Sivik J; Drabick JJ; Rybka W
Bone Marrow Transplant; 2009 Aug; 44(3):157-61. PubMed ID: 19204716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]